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Drug resistance emerges in an ecological context where ﬁtness
costs restrict the diversity of escape pathways. These pathways
are targets for drug discovery, and here we demonstrate that we
can identify small-molecule inhibitors that differentially target
resistant parasites. Combining wild-type and mutant-type inhib-
itors may prevent the emergence of competitively viable resis-
tance. We tested this hypothesis with a clinically derived chloro-
quine-resistant (CQr) malaria parasite and with parasites derived
by in vitro selection with Plasmodium falciparum dihydroorotate de-
hydrogenase (PfDHODH) inhibitors. We screened a chemical library
against CQs and CQr lines and discovered a drug-like compound (IDI-
3783) that was potent only in the CQr line. Surprisingly, in vitro
selection of Plasmodium falciparum resistant to IDI-3783 restored
CQ sensitivity, thereby indicating that CQmight once again be useful
as a malaria therapy. In parallel experiments, we selected P. falcipa-
rum lines resistant to structurally unrelated PfDHODH inhibitors
(Genz-666136 and DSM74). Both selections yielded resistant lines
with the same point mutation in PfDHODH:E182D. We discovered
a compound (IDI-6273) more potent against E182D than wild-type
parasites. Selection of the E182D mutant with IDI-6273 yielded a re-
version to the wild-type protein sequence and phenotype although
the nucleotide sequence was different. Importantly, selection with
a combination of Genz-669178, a wild-type PfDHODH inhibitor, and
IDI-6273, a mutant-selective PfDHODH inhibitor, did not yield re-
sistant parasites. These two examples demonstrate that the com-
promise between resistance and evolutionary ﬁtness can be
exploited to design therapies that prevent the emergence and
spread of resistant organisms.
evolution | target identiﬁcation | combination therapy
Malaria is a vector-borne infectious disease transmitted byfemale Anopheles mosquitoes and caused by protozoan
parasites of the genus Plasmodium. Malaria is widespread in
tropical and subtropical regions, including parts of the Americas,
Asia, and Africa. Malaria afﬂicts 350–500 million people each
year, resulting in ∼800,000 deaths per year (1). The majority of
malaria-related deaths occur in young children below the age of
ﬁve in Sub-Saharan Africa (1). Resistance has emerged to nearly
all antimalarial drugs, including the front-line artemisinin-based
combination therapies (2). Widespread resistance necessitates
both the discovery and development of new antimalarial thera-
pies as well as strategies to protect current and future therapies
from the threat of resistance. We explore here the possibility of
blocking the emergence of resistance with a population biology trap:
by identifying situations where resistance to one compound confers
hypersensitivity to another, we can design combination therapies
that not only kill the parasite, but also guide its evolution away from
resistance.
Drug resistance pathways in Plasmodium falciparum are sharply
limited by tradeoffs among growth, transmissibility, and resistance.
For example, there is a single dominant resistance-ﬁtness maximum
for the dihydrofolate reductase inhibitor pyrimethamine, and the
resistance phenotype is accessible by a very small number of
mutational pathways (3). Resistance pathways can be identiﬁed
through human or animal treatment failures or through in vitro
resistance selections. These strategies expose parasites to dif-
ferent selective pressures, and so do not necessarily yield identical
results. However, in vitro resistance selections have been key in
ethically predicting resistance pathways, including identifying
pfmdr1 as a resistance locus for meﬂoquine (4).
Resistance has ﬁtness costs and can leave organisms vulnera-
ble to other stresses. For example, M184V/I mutations in HIV-1
reverse transcriptase confer resistance to nucleoside reverse tran-
scriptase inhibitors such as lamivudine. However, these mutants are
hypersensitive to zidovudine, stavudine, and tenofovir-DF and have
a compromised ability to incorporate natural nucleotide substrates
(5). Point mutations in the BCR-ABL kinase that drives chronic
myeloid leukemia can give resistance to imatinib (6), but these
differ in their transforming ability. In addition, second-generation
BCR-ABL inhibitors such as nilotinib and dasatinib successfully
target many of the imatinib-resistant kinases (7). From these obser-
vations, we propose that drug resistance creates a tractable target
for drug discovery.
Signiﬁcance
Drug resistance is a major problem in treating malaria infec-
tions. Resistance pathways are limited by evolutionary ﬁtness
constraints, and these pathways can be anticipated and pre-
emptively blocked. We identiﬁed compounds selective for
mutant malaria parasites that are resistant to either clinically
used (chloroquine) or in-development dihydroorotate dehydro-
genase (DHODH) inhibitor therapies. In both cases, resistance
selections of mutant parasites with the matching mutant-selec-
tive drug led to a reversion to the wild-type phenotype. Addi-
tionally, combination selection of wild-type parasites with paired
wild-type and mutant-type DHODH inhibitors failed to produce
resistant parasites. These ﬁndings indicate that pairing inhibitors
that target the bulk wild-type population and the small, emerg-
ing resistant population can suppress the rise and spread of
drug resistance.
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We set out to identify inhibitors that selectively targeted drug-
resistant P. falciparum mutant parasites. We then used these
mutant-selective inhibitors to drive parasite evolution toward a
wild-type phenotype. To do so, we performed two sets of experi-
ments: one with an existing, clinically-relevant chloroquine-resistant
(CQr) mutant, and the other with de novo-derived resistance to in-
development dihydroorotate dehydrogenase (PfDHODH) inhibitors.
CQ resistance is widespread in the ﬁeld and is proposed to
have occurred through at least four independent founder events:
one in Asia that spread to Africa (K76T in the chloroquine re-
sistance transporter PfCRT), one in Papua New Guinea, and two
in South America. These mutations spread across the globe in
only 20–80 sexual generations due to strong directional selective
sweeps (8). Despite selective sweeps, CQ resistance has a ﬁtness
cost and is untenable in the absence of drug. For example, CQ
sensitivity returned to Malawi after a 12-y CQ absence (9). As
CQ is widely-used, economical, and one of very few antimalarials
safe for use during pregnancy, a method for restoring CQ’s
effectiveness and protecting against future resistance would be
tremendously valuable.
Verapamil and related “sensitizer” compounds have been
shown to reverse chloroquine resistance. When used alone, ve-
rapamil has only modest effects against P. falciparum, with IC50
values in the range of 6–8 μg/mL in culture. However, sub-
therapeutic doses of verapamil restored CQ sensitivity to the
CQ-resistant line W2 and had no effect on the CQ-sensitive line
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Fig. 1. Chloroquine and IDI-3783 resistance are mutually exclusive. (A) The thiazepine amide IDI-3783 is highly potent against CQr parasites (Dd2, black bars)
while demonstrating μM activity against CQs parasites (3D7, white bars). Selection of the Dd2 parental line with IDI-3783 led to a highly signiﬁcant increase in
EC50 (***P ≤ 0.0001) rendering the parasites resistant to the compound (Dd2: Q352R, gray bars). (B) Selection for IDI-3783–resistant parasites results in
a signiﬁcant decrease in chloroquine EC50 (***P ≤ 0.0001) rendering them sensitive to the drug at levels comparable to 3D7. (C and D) The control compounds
atovaquone and meﬂoquine do not demonstrate signiﬁcant changes in EC50 between the parasite lines tested (n.s., not signiﬁcant). (E) Topology prediction
of PfCRT showing the location of the Q352R amino acid change in the IDI-3783–resistant parasites (red dot). The remainder of the sequence was unchanged
relative to the Dd2 parent, including the important K76T mutation found in CQr parasites, highlighted in yellow. EC50 values were determined using a whole-
cell SYBR Green assay (28). Error bars indicate the SD of three biological replicates, each with triplicate measurements. Signiﬁcance relative to Dd2 EC50 was
determined by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison post test; n = 3.
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Fig. 2. Genz-669178 and IDI-6273 resistance are mutually exclusive. (A) The wild-type PfDHODH inhibitor Genz-669178 is highly potent against wild-type 3D7
parasites (black bars) and weakly potent against parasites raised in a resistance selection (3D7 E182D, white bars) (***P < 0.0001). Sequential selection of the
3D7 E182D line with IDI-6273, a PfDHODH-E182D selective inhibitor, led to increased sensitivity to Genz-669178 (3D7 E182D: D182E, gray bars) (***P <
0.0001). However, the revertant was signiﬁcantly different from the 3D7 wild-type (**P < 0.001). (B) DSM74 is highly potent against wild-type 3D7 parasites
(black bars), and weakly potent against parasites raised in a resistance selection (3D7 E182D, white bars) (***P < 0.0001). The 3D7 E182D: D182E revertant
regained sensitivity to DSM74 (***P < 0.0002). The revertant was not signiﬁcantly different from the wild-type 3D7 (n.s., not signiﬁcant). (C) IDI-6253 shows
no signiﬁcant difference between 3D7 and 3D7 E182D, but it is less potent against the 3D7 E182D: D182E wild-type revertant (**P = 0.0043). (D) The mutant
PfDHODH inhibitor IDI-6273 is highly potent against 3D7 E182D, but much less so against wild-type 3D7 or the wild-type revertant 3D7 E182D: D182E (***P <
0.0001). The 3D7 E182D: D182E wild-type revertant is signiﬁcantly different from the 3D7 wild-type (***P < 0.0001). (E) GSK-3 is highly potent against 3D7
and is markedly less potent against 3D7 E182D (***P < 0.0001). The 3D7 E182D: D182E wild-type revertant shows no signiﬁcant difference with wild-type 3D7.
(F) The control compound dihydroartemisinin does not demonstrate signiﬁcant changes in EC50 between the parasite lines tested (n.s., not signiﬁcant). (G)
Sequence alignment showing nucleotide changes in the pfdhodh gene. The remainder of the sequence was unchanged relative to the 3D7 parent. EC50 values
were calculated using a whole-cell SYBR Green (28) assay. Error bars indicate the SD of three biological replicates, each with triplicate measurements. Sig-
niﬁcance relative to 3D7: E182D EC50 was determined by one-way ANOVA with Tukey’s multiple comparison post test; n =3. (H) Residue E182 lines the drug-
binding site of PfDHODH and makes a salt bridge with R262. This interaction may be important for holding the helix-turn-helix lid of the binding pocket
against the body of the protein. The shortened side chain in an E182D mutant may weaken this interaction, affecting drug binding to this pocket. The image
was prepared using PDB code 3o8a with CCP4mg software (30).
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D6 (10). This sensitization was later shown to extend across
multiple CQ-resistant lines (11), suggesting a general mechanism
for resistance. Later studies demonstrated that verapamil interferes
with CQ transport through the Plasmodium falciparum chloro-
quine resistance transporter (PfCRT), which efﬂuxes CQ from
the food vacuole (12). Verapamil has a relatively modest ﬁvefold
effect (13), and it has not been used clinically in its 25-y history as
an antimalarial sensitizer. A more potent, more drug-like sensi-
tizer to restore the efﬁcacy of chloroquine, malaria’s “spent magic
bullet” (14), would be useful.
DHODH is an enzyme that catalyzes the rate-limiting step of
pyrimidine biosynthesis. Malaria parasites lack pyrimidine sal-
vage pathways and are thus reliant upon de novo biosynthesis.
Although humans and Plasmodium both have class II DHODH
enzymes, crystal structures have shown substantial differences in
the pocket where all known inhibitors bind (15). Multiple groups
are developing PfDHODH inhibitors (16), and DHODH is
considered a promising target for the future of antimalarial
chemotherapy (17). We sought to catalog DHODH resistance
mechanisms and then develop strategies to contain and suppress
resistance before clinical deployment.
Results and Discussion
We performed a high-throughput small-molecule screen against
both CQs and CQr parasite lines to identify compounds differ-
entially active in the CQr parasites. The screening effort pro-
vided a cluster of fourteen 1,4-dibenzothiazepene amides. Of
these screening hits, compound IDI-3783 was resynthesized and
shown to have an EC50 of 3 nM in the CQ
r Dd2 strain compared
with >10 μM EC50 against wild-type 3D7 parasites (Fig. 1 A and
B). Resistance selections were carried out in Dd2 parasites using
IDI-3783 at 10-fold the EC50 concentration. Drug-resistant par-
asites emerged after 35 d that showed a 1,000-fold increase in the
EC50 for IDI-3783, shifting from 3 nM to 4,000 nM. Surprisingly,
IDI-3783 resistance was coupled with restored sensitivity to CQ,
with the CQ EC50 dropping from 100 nM to 14 nM, a 10-fold shift
(Fig. 1C). IDI-3783 acts synergistically with CQ when adminis-
tered together, implying that IDI-3783 blocks the efﬂux of CQ
through PfCRT K76T in addition to its own toxic effect (Fig. S1).
The EC50 of atovaquone and meﬂoquine, both unrelated anti-
malarial drugs, was unchanged between the sensitive and resistant
parasites (Fig. 1D and Table S1).
Whole-genome sequencing of the IDI-3783-resistant Dd2
parasite revealed a Q352R mutation in PfCRT, in the ninth
transmembrane segment of the protein (Fig. 1E). The preexist-
ing K76T mutation reduces the positive character of the PfCRT
channel, and this more neutral milieu is believed to allow pro-
tonated, positively charged CQ to leave the food vacuole (18),
thereby preventing accumulation of toxic concentrations of drug.
The Q352R mutation reintroduces positive charge into the
PfCRT channel, thereby restoring sensitivity to CQ by preventing
efﬂux. The behavior of the Q352R mutation is consistent with
a model where IDI-3783 inhibits the channel function of PfCRT
in the presence of the K76T CQr mutation, and that introduction
of the Q352R mutation to PfCRT simultaneously disrupts IDI-
3783 activity and prevents the efﬂux of CQ from the food vac-
uole. From these results, a new type of combination therapy
might be proposed even in the face of widespread CQ resistance
in the ﬁeld: namely, the combination of CQ and a molecule that
kills CQr parasites.
To extend these ﬁndings, we hypothesized that we could an-
ticipate the emergence of resistance for molecules in the drug-
development pipeline. To test this hypothesis, we focused on
dihydroorotate dehydrogenase (DHODH). We developed an
enzyme assay for P. falciparum dihydroorotate dehydrogenase
(PfDHODH) and initiated an HTS campaign that identiﬁed
a unique chemotype, 5-benzimidazolyl-N-alkylthiophene-2-car-
boxamide, as an inhibitor of PfDHODH (Fig. 2A) (Genz-669178)
(16, 19). The alkylthiophene inhibitors have low nanomolar po-
tency against puriﬁed enzyme and excellent selectivity against
human DHODH. Further investigations of these compounds
showed potency at double-digit nanomolar concentrations against
P. falciparum in vitro and were also found to be efﬁcacious against
the rodent malaria parasite Plasmodium berghei in vivo (16).
Phillips and co-workers (20, 21) have also published a novel series
of triazolopyrimidine-based PfDHODH inhibitors with compara-
ble activity.
We conducted resistance selections using either a representa-
tive alkylthiophene inhibitor (Genz-666136) or a triazolopyr-
imidine inhibitor (DSM74) in wild-type 3D7 parasites. Resistant
parasites from these selections were subjected to targeted se-
quencing of the pfdhodh gene and whole-genome sequencing.
Both compounds independently selected an E182D mutation in
PfDHODH, indicating that the E182D mutation may be an
optimal ﬁtness–resistance compromise. E182 resides in the lid of
the PfDHODH species-selective inhibitor site (Fig. 2H) (22).
To further characterize the 3D7 E182D PfDHODH inhibitor-
resistant parasites, we rescreened 59 compounds from our earlier
HTS and two compounds from a similar program at Glax-
oSmithKline against the resistant line. In this small set, we found
examples of compounds more potent against 3D7 E182D than
3D7. Compound IDI-6273 (Fig. 2D) was 10.95-fold more active
against 3D7 E182D than 3D7, with EC50 values of 2,300 nM for
the 3D7 parent improving to 210 nM for 3D7 E182D. Further
resistance selections were carried out in the 3D7 E182D para-
sites with IDI-6273. Drug-resistant parasites emerged after 41 d.
These parasites showed a 19-fold increase in the EC50 for IDI-
6273, shifting from 210 nM in the 3D7 E182D parent to 4,000
nM in the newly resistant line. Both selections had no effect on
response to dihydroartemisinin, a control compound (Fig. 2F
and Table S2).
Sequencing the pfdhodh gene in the 3D7 E182D selected line
uncovered another mutation in codon 182: GAT became GAG.
This nucleotide mutation resulted in a reversion to the wild-type
3D7 protein sequence (Fig. 2G). Thus, the sequentially selected
line is 3D7 E182D: D182E. Although it is promising that se-
quential selection of a mutant parasite with a mutant-selective
inhibitor led to a wild-type reversion, the relatively long timeline
under single-drug pressure increases the chances of compensa-
tory ﬁtness mutations that could bolster a less-ﬁt resistance
pathway and allow it to emerge and spread.
To limit the risk of minor variant resistance pathways, we
tested simultaneous selection of a wild-type population with both
a wild-type and mutant-type inhibitor. When dosed together,
these compounds are highly synergistic (Fig. S1). Simultaneous
selection with IDI-6273 and Genz-669178, a later derivative of
the Genz-666136 used to produce the 3D7 E182D line, did not
yield any drug-resistant parasites in forty generations of exposure
(80 d) (Fig. 3 and Table S3). This result supports the idea of
combining compounds that target wild-type and resistant parasites
for treating malaria and reducing the risk of developing resistance.
All compounds used in this study were synthesized as described or
purchased (Table S4).
The two examples described have shown that resistant para-
sites are hypersensitive to other agents. Sequential treatment
with these potentiated agents resulted in an evolutionary loop
back to wild-type sensitivity to the initial treatment. In the example
of CQ, this phenotypic reversion occurred through a unique
mutation in the PfCRT channel. In the example of PfDHODH in-
hibitors, the phenotypic reversion occurred through a mutation
restoring the wild-type protein sequence of PfDHODH. Simul-
taneous rather than sequential treatment with both the wild-type
and mutant-selective PfDHODH inhibitors failed to give para-
sites resistant to either compound. We believe that evolutionary
ﬁtness constraints allow few pathways to resistance, and these
pathways can be anticipated and preemptively blocked. It would
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be interesting to extend this work to suppressive combinations, as
they have been demonstrated to prevent the emergence and spread
of resistant bacteria (23) and could do the same in malaria.
Another possible direction is to combine wild-type and mutant-
selective inhibitors into a single bifunctional molecule, as in the
natural product DNA gyrase inhibitor simocyclinone D8 (24). The
combination of well-chosen anti-malarial agents active against
sensitive and resistant parasites effectively kills parasites in the
short-term and, in the long-term, can help shape evolution away
from the development of drug resistance.
Materials and Methods
Resistance Selection. Approximately 2 × 108 mixed stage parasites were
treated at 30 nM IDI-3783 or 480 nM Genz-666136 for 6–8 d in each of three
independent ﬂasks to eliminate all parasites visible by microscopy. After this
treatment, compound pressure was removed, and the cultures were fed on
alternate days with complete compound-free RPMI media. Once healthy
parasites reappeared in the culture ﬂasks and parasitemia reached 2–4%,
compound exposure was repeated. These steps were executed for 30–60 d
until the parasites were growing in the presence of compound at a typical
multiplication rate. To compensate for the lysis of red blood cells, 30–40% of
parasite culture was replaced with freshly washed cells once a week during
the entire selection period. Selected parasites were cloned by limiting di-
lution in a 96-well plate in the presence of 30 nM IDI-3783 or 500 nM Genz-
666136, with an inoculum of 0.2 infected RBCs per well. Parasite clones were
detected after 3 wk of growth by thin smear microscopy. Frozen stocks of
resistant parasites were prepared using Glycerolyte 57 (Baxter Healthcare).
Genomic DNA Extraction and PCR Resequencing. Genomic DNA extractions
from parasites were performed using Qiagen DNeasy kit (Qiagen) for whole-
genome sequencing and mutation analysis of the pfdhodh (PlasmoDB ID:
PFF0160c) gene. A 2.2-kb fragment encompassing the complete pfdhodh
ORF was PCR ampliﬁed from Genz-666136-resistant clones and parental
lines. PCR-ampliﬁed fragments were subcloned and fully sequenced from
both strands using T7, M13-reverse and pfdhodh- speciﬁc primers.
Whole-Genome Sequencing and Analysis. Genomic DNA was sheared and
made into a 200-bp fragment Illumina sequencing library and sequencedwith
paired-end reads on an Illumina GAIIx machine. The sequenced reads were
aligned against the P. falciparum 3D7 reference from PlasmoDB (version
7.1*) (25) using BWA version 0.5.7 (20). Duplicate reads were marked using
the Picard MarkDuplicates tool (http://picard.sourceforge.net/). The consen-
sus bases were called using the Genome Analysis Toolkit’s (GATK) Uniﬁed
Genotyper (version 1.0.5974) (26) and the SAMtools (version 0.1.16) (27)
mpileup command. Only bases that were called as homozygous for the
reference or the alternate allele with a genotype quality of at least 30 were
considered. The GATK Uniﬁed Genotyper called 3,685 SNPs in the Genz-
666136-resistant strain relative to stock (2,108 intergenic, 248 intronic, 423
synonymous coding, and 906 nonsynonymous coding). By contrast, only 47
SNPs passed all of the quality ﬁlters when using the SAMtools genotyper (25
intergenic, 2 intronic, 3 synonymous, 17 nonsynonymous). Of these, only
eight overlapped with the GATK set (2 intergenic and 6 nonsynonymous).
The nonsynonymous mutations fell in four genes: (i) F227I in PFF0160c (the
dhodh gene), (ii) I352T and E355D in PF07_0111, a highly polymorphic gene
of unknown function, (iii) adjacent mutations in the PfEMP PF08_0106, and
(iv) I1548M in PFI1280c, a putative protein kinase that is also highly
polymorphic.
In Vitro Drug Sensitivity and EC50 Determinations. Drug susceptibility was
measured using the SYBR Green method (28). Twelve-point curves based
on twofold dilutions of the test compound were carried out in triplicate
each day and replicated on three different days. EC50 values were calcu-
lated using a nonlinear regression curve ﬁt in Prism 5.0 for Mac (Graph-
Pad Software, Inc.).
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Fig. 3. Combination selection with Genz-669178 and IDI-6273 fails to give resistance. (A–C) Sensitivity to the PfDHODH inhibitors Genz-669178, IDI-6273, and
GSK-3 are unchanged after 40 generations of dual selection (n.s., not signiﬁcant). (D–F) Sensitivity to the unrelated control compounds chloroquine,
cycloguanil, is unchanged (n.s., not signiﬁcant). EC50 values were calculated using a whole-cell SYBR Green (28) assay. Error bars indicate the SD of three
biological replicates, each with triplicate measurements. Signiﬁcance relative to Dd2 EC50 was determined by one-way ANOVA with Tukey’s multiple com-
parison post test; n =3.
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Isobologram experiments were performed in similar fashion using the
modiﬁed ﬁxed-ratio methodology (29). Brieﬂy, IDI-3783 and CQ were mixed
at multiple ﬁxed volumetric ratios (10:0, 8:2, 6:4, 5:5, 4:6, 2:8, and 0:10) and
then serially diluted in 12-point twofold dilutions and dispensed in triplicate
to 384-well assay plates and replicated on two different days. Genz-669178
was tested in combination with IDI-6273 at multiple ﬁxed volumetric ratios
(15:0, 12:3, 9:6, 6:9, 3:12, and 0:15) and then serially diluted in 12-point
twofold dilutions and dispensed in triplicate to 384-well assay plates and
replicated on three different days. EC50 values were calculated as above, and
fractional inhibitory concentrations (FICs) were calculated for each drug
combination as described (29). Synergy was deﬁned as an FIC < 1.0, addi-
tivity as FIC = 1.0, and antagonism as FIC > 1.0.
Synthesis of DSM74. DSM74 was prepared following the literature procedure
(21) and was recrystallized from ethanol. 1H NMR spectra matched that
reported (20), and HPLC analysis indicated > 95% purity.
Synthesis of Genz-669178. Genz-669178 was prepared following the literature
procedure with 1H NMR spectra that matched those reported (19) and HPLC
analysis indicated >95% purity.
Statistical Analyses. EC50 data are shown as mean ± SD and were analyzed by
ANOVAwith multiple comparison post hoc tests (Prism 5; GraphPad Software, Inc.)
as noted in theﬁgure legends. Differences were considered signiﬁcant for P < 0.05.
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